• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内脏利什曼病:利用现有干预措施消除。

Visceral leishmaniasis: elimination with existing interventions.

机构信息

Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland.

出版信息

Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0.

DOI:10.1016/S1473-3099(10)70320-0
PMID:21453873
Abstract

The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.

摘要

通过更有效地利用现有干预措施,可大大减轻传染病给全球带来的负担。在病例发现、诊断和治疗策略方面的进展,使得人们有可能考虑在南亚次大陆消除内脏利什曼病。现在的当务之急是,通过在流行地区的村庄主动发现病例并在基层医疗中心用单剂量脂质体两性霉素 B 进行治疗,在社区层面切实执行现有干预措施。一旦达到每 10000 人口 1 例的消除目标,就可以引入米替福新和巴龙霉素联合疗法,以确保几种治疗内脏利什曼病药物的长期供应,并预防耐药性的产生。

相似文献

1
Visceral leishmaniasis: elimination with existing interventions.内脏利什曼病:利用现有干预措施消除。
Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0.
2
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.印度内脏利什曼病短程多药治疗与标准治疗的比较:一项开放标签、非劣效性、随机对照试验。
Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.
3
Combination therapy for visceral leishmaniasis.内脏利什曼病的联合治疗
Lancet. 2011 Feb 5;377(9764):443-4. doi: 10.1016/S0140-6736(10)62237-4. Epub 2011 Jan 20.
4
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.利用重点药物警戒确保孟加拉国国家黑热病消除规划中抗利什曼原虫药物的患者安全。
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.
5
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.印度次大陆内脏利什曼病联合疗法的成本效益分析。
PLoS Negl Trop Dis. 2010 Sep 7;4(9):e818. doi: 10.1371/journal.pntd.0000818.
6
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.在孟加拉国,使用两性霉素B脂质体、米替福新和巴龙霉素的短疗程联合方案治疗内脏利什曼病(VL)的安全性和有效性。
PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635. doi: 10.1371/journal.pntd.0005635. eCollection 2017 May.
7
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.2010年内脏利什曼病的治疗:来自印度比哈尔邦的指导意见。
Future Microbiol. 2010 Sep;5(9):1301-3. doi: 10.2217/fmb.10.92.
8
Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.印度次大陆的内脏利什曼病治疗:如何惠及最弱势群体。
Expert Rev Anti Infect Ther. 2012 Aug;10(8):839-41. doi: 10.1586/eri.12.71.
9
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?内脏利什曼病:诊断、治疗和控制方面有哪些需求?
Nat Rev Microbiol. 2007 Nov;5(11):873-82. doi: 10.1038/nrmicro1748.
10
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.米替福新和巴龙霉素联合治疗可延缓婴儿利什曼原虫实验性耐药的发生。
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005620. doi: 10.1371/journal.pntd.0005620. eCollection 2017 May.

引用本文的文献

1
Aurantoside L, a New Tetramic Acid Glycoside with Anti-Leishmanial Activity Isolated from the Marine Sponge .从海洋海绵中分离出的具有抗利什曼原虫活性的新四氢酸糖苷 Aurantoside L。
Mar Drugs. 2024 Apr 12;22(4):171. doi: 10.3390/md22040171.
2
Assessment of the impact of implementation research on the Visceral Leishmaniasis (VL) elimination efforts in Nepal.评估实施研究对尼泊尔内脏利什曼病(VL)消除工作的影响。
PLoS Negl Trop Dis. 2023 Nov 9;17(11):e0011714. doi: 10.1371/journal.pntd.0011714. eCollection 2023 Nov.
3
Liposomal drug delivery systems for the treatment of leishmaniasis.
用于治疗利什曼病的脂质体药物传递系统。
Parasitol Res. 2022 Nov;121(11):3073-3082. doi: 10.1007/s00436-022-07659-5. Epub 2022 Sep 16.
4
Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis.病例报告:低剂量脂质体两性霉素B在内脏利什曼病患者中的应用
Front Med (Lausanne). 2021 Nov 17;8:766400. doi: 10.3389/fmed.2021.766400. eCollection 2021.
5
Scoping review of Neglected Tropical Disease Interventions and Health Promotion: A framework for successful NTD interventions as evidenced by the literature.忽视热带病干预措施和健康促进的范围审查:文献证据表明成功的忽视热带病干预措施的框架。
PLoS Negl Trop Dis. 2021 Jul 6;15(7):e0009278. doi: 10.1371/journal.pntd.0009278. eCollection 2021 Jul.
6
Evaluation of Loopamp™ Detection Kit and Antigen ELISA for Post-Elimination Detection and Management of Visceral Leishmaniasis in Bangladesh.评价环介导等温扩增检测试剂盒和抗原酶联免疫吸附试验在孟加拉国消除后内脏利什曼病的检测和管理中的应用。
Front Cell Infect Microbiol. 2021 Apr 26;11:670759. doi: 10.3389/fcimb.2021.670759. eCollection 2021.
7
Immune Responses in Post Kala-azar Dermal Leishmaniasis.黑热病后皮肤利什曼病中的免疫反应
Indian J Dermatol. 2020 Nov-Dec;65(6):452-460. doi: 10.4103/ijd.IJD_258_20.
8
Trends in Recently Emerged Induced Cutaneous Leishmaniasis, Sri Lanka, for the First 13 Years.斯里兰卡新出现的诱导性皮肤利什曼病趋势,前 13 年。
Biomed Res Int. 2019 Apr 14;2019:4093603. doi: 10.1155/2019/4093603. eCollection 2019.
9
Assessment of quality of life using WHOQOL-BREF in patients with visceral leishmaniasis.采用 WHOQOL-BREF 量表评估内脏利什曼病患者的生活质量。
Health Qual Life Outcomes. 2019 Mar 28;17(1):53. doi: 10.1186/s12955-019-1112-2.
10
Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.印度内脏利什曼病消除目标,防止复发的策略。
Expert Rev Anti Infect Ther. 2018 Nov;16(11):805-812. doi: 10.1080/14787210.2018.1532790. Epub 2018 Oct 10.